Serum Brain-derived Neurotrophic Factor Levels Following Electroconvulsive Therapy in Treatment-resistant Depressed Patients

Objectives: To determine whether serum levels of brain-derived neurotrophic factor (BDNF) are associated with response to electroconvulsive therapy (ECT) in treatment-resistant depressed patients with a relatively longer period of measurement. Methods: This study included 30 Japanese unipolar depres...

Full description

Saved in:
Bibliographic Details
Published inJournal of St. Marianna University Vol. 6; no. 2; pp. 253 - 261
Main Authors Haga, Toshiaki, Yamaguchi, Noboru, Maedomari, Mioto, Higuchi, Hisashi, Sasaki, Oga, Kamata, Mitsuhiro, Nishio, Takashi
Format Journal Article
LanguageEnglish
Japanese
Published St. Marianna University Society of Medical Science 2015
St.Marianna University Society of Medical Science
Subjects
Online AccessGet full text
ISSN2185-1336
2189-0277
DOI10.17264/stmarieng.6.253

Cover

More Information
Summary:Objectives: To determine whether serum levels of brain-derived neurotrophic factor (BDNF) are associated with response to electroconvulsive therapy (ECT) in treatment-resistant depressed patients with a relatively longer period of measurement. Methods: This study included 30 Japanese unipolar depressed patients with current major depressive episode. Montgomery-Äsberg Depression Rating Scale (MADRS) score was ≥21 in all subjects. ECT was performed twice a week for a total of 4–10 sessions. Serum BDNF levels were measured before ECT (T0), the day after the last ECT session (T1), and 1 month after the last ECT session (T2). Patient response to treatment was defined as a ≥50% decrease compared with the pretreatment total MADRS score. Results: Serum BDNF levels showed no significant variation among the patients during the entire study period. In responders, serum BDNF levels showed a progressive increase, and the differences between T0 and T1 and between T0 and T2 were significant (p=0.022 and p=0.007, respectively). In non-responders, serum BDNF levels showed a progressive decrease, and the difference between T0 and T2 was significant (p=0.012). No significant association was identified between change in serum BDNF level and change in total MADRS score in any of the patients following ECT. Conclusions: The present results showed that serum BDNF levels after ECT increased progressively in responders, but not in non-responders. Our results provide important information for understanding the exact role of BDNF in the antidepressive effects of ECT.
ISSN:2185-1336
2189-0277
DOI:10.17264/stmarieng.6.253